SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/22/2017 7:18:18 PM - Followers: 65 - Board type: Free - Posts Today: 0


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

SureTrader
Interactive Brokers Advertisement
ZYNE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Statement of Changes in Beneficial Ownership (4) 07:26 PM
ZYNE News: Current Report Filing (8-k) 10/11/2017 08:01:50 AM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 10/03/2017 04:09:06 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 10/03/2017 04:08:13 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 10/03/2017 04:07:22 PM
News News Alert: Statement of Changes in Beneficial Ownership (4) 10/23/2017 07:26:26 PM
PostSubject
#890   And off we go! Probably last chance buy LittleBird 10/02/17 11:20:47 AM
#889   Bottom line the key was to reload on cjstocksup 10/02/17 11:12:58 AM
#888   Thank you LB. midas716 10/02/17 10:34:28 AM
#887   Here is the link for the Cantor Fitz upgrade: LittleBird 10/02/17 10:30:45 AM
#886   It's linked through the stock app I use. LittleBird 10/02/17 10:26:00 AM
#885   This hasn't come across Fidelity news. Where are midas716 10/02/17 10:15:08 AM
#884   Huge upgrades, volume gonna pop here stocky101 10/02/17 10:06:01 AM
#883   Cantor Fitzgerald just upgraded rating from Neutral to Overweight. LittleBird 10/02/17 09:45:49 AM
#882   The stock just turned bullish stocky101 10/02/17 09:36:26 AM
#881   I don't believe this will come down to midas716 10/02/17 08:31:41 AM
#880   Good morning folks stocky101 10/02/17 07:26:37 AM
#879   Yes i added pretty good at 8.60 and Bescaredxx 10/01/17 12:27:07 PM
#878   Just wondering if the shorts can fill that MD-420 10/01/17 12:08:42 PM
#877   Yes and unfortunately shorts are still in control! Bescaredxx 10/01/17 12:00:43 PM
#876   That's what I thought when I read the MD-420 10/01/17 11:57:24 AM
#875   $ZYNE$ Great update. Thanks for the info. Very helpful. surfgreen 09/30/17 04:58:10 PM
#874   I have had two meetings with the VP Bescaredxx 09/30/17 12:16:05 AM
#873   45,000 shares bought @ $11.49 in after market stocky101 09/29/17 04:42:29 PM
#872   $25.95 is 52 week high stocky101 09/29/17 03:47:46 PM
#871   I thought for sure we would’ve talked today stocky101 09/29/17 03:44:57 PM
#870   Aren't enough catalyst till next year and they surfgreen 09/29/17 01:47:51 PM
#869   EDGX and NSDQ are literally killing this stock midas716 09/29/17 01:37:14 PM
#868   My TdAmeritrade showing Cancaccord Genuity upgrading the price stocky101 09/29/17 01:34:17 PM
#867   Need to hold here and go parabolic again midas716 09/29/17 01:34:05 PM
#866   Let the breakout begin.... See ya shorts stocky101 09/29/17 01:15:39 PM
#865   I'm guessing the analysts are clueless. midas716 09/29/17 12:24:18 PM
#864   Are analyst updates expected to be published today? LittleBird 09/29/17 12:13:18 PM
#863   When? Apparently traders didn't get the memo. Lol. midas716 09/29/17 12:09:21 PM
#862   Load up, huge run coming with huge upgrade stocky101 09/29/17 10:40:26 AM
#861   Just added 5000 more stocky101 09/29/17 10:29:22 AM
#860   ZYNE Pre-Market midas716 09/29/17 09:07:19 AM
#859   Analyst Actions: Piper Jaffray Upgrades Zynerba Pharmaceuticals to RandolRocketman 09/29/17 08:33:17 AM
#858   Safe trading tip: If you don't see a bobbodom 09/29/17 08:01:44 AM
#857   I'll take the 13 for the 2000 I midas716 09/28/17 05:34:07 PM
#856   Yep and another fool put more there. I cjstocksup 09/28/17 05:20:49 PM
#855   Big money just blasted through 17,345 shares at 10.00. midas716 09/28/17 05:18:37 PM
#854   The big money that was in at $20.00 cjstocksup 09/28/17 05:07:34 PM
#853   ZYNE is at 10.03 in after hours trading. ;) midas716 09/28/17 05:03:58 PM
#852   Check out this aftermarket action stocky101 09/28/17 05:00:58 PM
#851   I agree 100%. On this news ZYNE should cjstocksup 09/28/17 04:49:03 PM
#850   I'm expecting a huge bounce tomorrow with upgrades, stocky101 09/28/17 04:24:20 PM
#849   My lucky day. Sold ZYNE at 12.50 pre-market Digging420 09/28/17 04:22:25 PM
#848   Shorts are playing a dangerous game here with cjstocksup 09/28/17 02:29:27 PM
#847   I'm game. Been in and out of ZYNE midas716 09/28/17 02:26:54 PM
#846   Exactly. ZYNE could be back over $20.00 in cjstocksup 09/28/17 02:15:30 PM
#845   Agree. These prices are a steal. Well funded, surfgreen 09/28/17 02:09:21 PM
#844   I am holding ZYNE is a great investment now. cjstocksup 09/28/17 01:55:02 PM
#843   They shorted big-time this morning and killed the Pedro2004 09/28/17 01:51:19 PM
#842   9.51 9.52 bottom? Double bottom there on the midas716 09/28/17 12:20:18 PM
#841   I just sold one of my other Stocks stocky101 09/28/17 12:15:44 PM
PostSubject